When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed.
about
A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trialUpdates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm MeetingReadmission for Acute Exacerbation within 30 Days of Discharge Is Associated with a Subsequent Progressive Increase in Mortality Risk in COPD Patients: A Long-Term Observational Study.Number needed to treat (NNT) in clinical literature: an appraisal.Asthma and risk of breakthrough varicella infection in children.Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by.Antibiotic Prophylaxis in Orbital Fractures.Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Quetiapine extended release for the treatment of bipolar disorder.Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Treatment of bipolar depression: making sensible decisions.Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone.A primer on binge eating disorder diagnosis and management.Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis.Cost-Savings From an Antipsychotic Tablet-Splitting Program.Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons.How have research questions and methods used in clinical trials published in Clinical Rehabilitation changed over the last 30 years?Quantifying clinical relevance.Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials.Comparison of two combinations of opioid and non-opioid analgesics for acute periradicular abscess: a randomized clinical trial.Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed.Paging Dr Cohen, Paging Dr Cohen... An effect size interpretation is required STAT!: visualising effect size and an interview with Kristoffer Magnusson.Recovery after intracorporeal anastomosis in laparoscopic right hemicolectomy: a systematic review and meta-analysis.Liraglutide subcutaneous injection for weight loss: where does it fit?Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Methods for Incorporating Patient Preferences for Treatments of Depression in Community Mental Health Settings.The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out.Mindfulness-based cognitive therapy for recurrent depression: A translational research study with 2-year follow-up.Placebo-Controlled Trial of Familiar Auditory Sensory Training for Acute Severe Traumatic Brain Injury: A Preliminary Report.Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting.Guidelines for statistical reporting in the British Journal of Dermatology.Can the quality and clinical relevance of Equine Veterinary Journal publications be improved? A time for reflection and refinement.Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials.
P2860
Q30353864-A6FA1733-4120-44A5-A7C6-B35C858BBFF6Q34369664-5CE378B1-7F0B-40DB-8DA3-94EC4CF994D6Q34501911-5DC2F315-5F1C-471E-8F8E-59A080117ED3Q35038925-9E39D239-D95C-4E08-90E3-B78912B662E6Q35822379-2A18F544-A83B-4711-9C0E-D0FF7F7D1A4BQ35946331-1E591125-FB94-42A8-94C8-8520DB742A58Q36389996-D298728B-C4F6-4725-95D5-B6416A42869EQ36841455-277C8BD6-D090-44F5-92EC-F11622F58297Q37362082-E93F08FC-28AC-451C-B393-0D87E5D4723BQ37717432-06B7D47F-DFC0-40F5-939D-641CA3E003DBQ38156001-87889FD3-A117-47CC-886E-E0FDBF5AE838Q38237319-AC02F913-7535-4C9D-BA39-3DE400439E93Q38250849-470129E5-2903-4092-986F-6A0F6C049036Q38269372-0BF443BA-2FEC-4216-A72E-96906EDAF929Q38370764-8DCE9E6C-60C0-4121-B59A-6A8860896C37Q38587979-C535A510-BEF6-4983-B787-C3B39F4B3513Q38673549-1F11E6F9-F12D-495F-9D1F-3E154EF85EAAQ38718345-BEB27106-E169-4549-A1BB-A542F019861FQ38789841-96A9E75F-3B17-4FBA-8D08-548FA5378B29Q38931021-85477475-BD03-41C3-8874-5F26E17A82EDQ39349720-CEBA165A-1E94-44C9-B977-7F20C7DF4E91Q39550978-4BAB70DF-FF38-4B10-A3F1-CFFBD61D871DQ40633256-4A87DAF2-5E08-45A9-90BC-CA0816B64E86Q41769033-2BC2823A-BABC-4560-A621-17051635D96CQ42061953-F8AC65F4-1E77-413C-AE3E-2CA2F62C4C39Q44350182-010ABF8C-E369-4574-86C4-F3DBEBDBD19DQ46754794-AD2CAD63-36A9-445E-BB53-4FD60E0126E4Q47175106-70806D0A-3B0E-41CB-8B25-0FE939EF6923Q47320071-B081FF40-C826-4566-8F7A-A5E0333493A1Q47378089-557EBD80-7BE8-45DB-A198-CB8978DE77B6Q47675010-843A2FB7-AB65-4235-A31F-B62C0DB777B3Q47996519-A15F755A-94F6-436B-B277-F9D053296A35Q48072363-040A94A5-5848-4190-97C6-23C563B02B6EQ48127403-4C4AB037-4CEE-4843-BC96-97D7E1576A34Q48340843-B601B05C-46A4-4355-A3EE-66C506CFEC15Q48364163-0BD7B4D5-B732-4FE2-ADCC-081C4681A3B2Q49210038-1CA285B4-0764-4239-AAAD-BCE8FB20B88CQ50882836-A43A58FD-02B1-4D16-97DD-5A7E0249F1D8Q50905003-37D18D90-0FFE-41DE-8A7E-70B97F9307A9Q52613387-7B7C730B-ED90-47F7-8F35-7039CE3AE577
P2860
When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
When does a difference make a ...... lihood to be helped or harmed.
@en
type
label
When does a difference make a ...... lihood to be helped or harmed.
@en
prefLabel
When does a difference make a ...... lihood to be helped or harmed.
@en
P2860
P356
P1476
When does a difference make a ...... lihood to be helped or harmed.
@en
P2093
T A Ketter
P2860
P304
P356
10.1111/IJCP.12142
P577
2013-05-01T00:00:00Z